Clinical trials: Hodgkin Lymphoma
Mild, Moderate and Severe Persistent Asthma as Defined by NHLBI-2 Guidelines
Asthma In-Home Monitoring (AIM) Trial
OBJECTIVE: Determine whether home asthma telemonitoring using store-and-forward technology improves outcomes when compared to in-person, office-based visits.
- Trial name
- NCT00282516
- Testing
- In-home telemonitoring of pediatric patients with persistent asthma
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Tripler Army Medical Center
Leukemia, Lymphoma
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00085449
- Testing
- alemtuzumab, cyclosporine, fludarabine phosphate
- Where
- 24 sites in United States
- Sponsor
- Alliance for Clinical Trials in Oncology
Hepatitis c
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas
Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
- Trial name
- NCT02762448
- Testing
- Daclatasvir+ Asunaprevir
- Sponsor
- Tainan Municipal Hospital
Lymphoma
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma (ALCL 99)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- ALCL 99 (NCT00006455)
- Testing
- cyclophosphamide, cytarabine, dexamethasone
- Where
- 10 sites in Austria, Belgium and 8 more
- Volunteers
- 885 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Lymphoma, Follicular
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
- Trial name
- NCT05228158
- Testing
- Tazemetostat
- Where
- 135 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Eisai Co., Ltd.
Diffuse Large B-cell Lymphoma
Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCL
This retrospective study aimed to investigate the combined prognostic values of intratumoral metabolic heterogeneity (MH), disseminate feature (Dmax) and total metabolic tumor volume (TMTV) by 2-deoxy-2-[18F]fluoro-D-glucose…
- Trial name
- NCT05113576
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Neoplasms, Lymphoma, Non-Hodgkin
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
PD-0332991 may work in cancer by stopping cancer cells from multiplying. PD-0332991 is in a new class of drugs called cyclin-dependent kinase (CDK inhibitors).
- Trial name
- NCT00141297
- Testing
- PD-0332991
- Where
- 4 sites in United States
- Volunteers
- 74 people
- Sponsor
- Pfizer
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause.
- Conditions
- Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
- Trial name
- NCT03922724
- Testing
- ATL-RIC, mRIC, allo HCT
- Where
- 2 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
T Cell Lymphoma
Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma
The role of angiogenesis has been less clear in lymphoma than in solid tumors, in part related to the heterogeneity of disease and technical issues.
- Trial name
- PTCL (NCT00974324)
- Testing
- endostar and CHOP
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fudan University
CTCL/ Mycosis Fungoides
Diagnostic Classifier for Cutaneous T-cell Lymphomas
Primary cutaneous T-cell lymphomas (CTCL) are a form of skin cancer that is derived from immune cells. The most common form of CTCL is mycosis fungoides (MF).
- Trial name
- NCT04491825
- Testing
- Skin suction blistering and skin biopsies
- Where
- Austria
- Volunteers
- 160 people
- Sponsor
- Medical University of Vienna
Lymphoma, Non-Hodgkin
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
This is a multicenter, open-label, dose-finding study of venetoclax administered orally in combination with rituximab (R) or obinutuzumab (G) and standard doses of cyclophosphamide, doxorubicin, vincristine and oral prednisone…
- Trial name
- NCT02055820
- Testing
- Venetoclax, Cyclophosphamide, Obinutuzumab
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 267 people
- Sponsor
- Hoffmann-La Roche
Hodgkin Lymphoma, Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
The first part of the study is to evaluate and determine if three different forms of MGCD0103 (free base FB-MGCD0103, tartaric acid free base [TA-FB-MGCD0103], and dihydrobromide [2HBr] salt formulation MGCD0103) have the same…
- Trial name
- NCT00543582
- Testing
- MGCD0103 and Azacitidine
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- Mirati Therapeutics Inc.
B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia
CD19-Specific T Cells Post AlloSCT
This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small…
- Conditions
- B Acute Lymphoblastic Leukemia With t(v;11q23.3); KMT2A Rearranged, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03579888
- Testing
- Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Hodgkin Lymphoma
Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma
This study is being done to test the safety and effectiveness of pembrolizumab followed by radiation therapy in Hodgkin lymphoma.
- Trial name
- NCT03179917
- Testing
- Pembrolizumab, Involved Site Radiation Therapy
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatic Insufficiency, Liver Diseases
A Study to Evaluate the Pharmacokinetics and Safety of INCB161734 in Participants With Hepatic Impairment
This study is conducted to evaluate the pharmacokinetics and safety of INCB161734 in participants with hepatic impairment.
- Trial name
- NCT07853040
- Testing
- INCB161734
- Volunteers
- 24 people
- Sponsor
- Incyte Corporation
B-cell Lymphoma
Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas
Multicenter prospective open-label non-randomised phase I/II study in patients with relapsed or refractory CD20-positive aggressive lymphomas Phase I: Dose escalation of methotrexate and cytarabine (days 1, 8 and 15 of each…
- Trial name
- LeMLAR (NCT01788189)
- Testing
- Lenalidomide
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- University Hospital, Essen
Non Hodgkin Lymphoma, Hodgkin Lymphoma
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving disease eradication in patients with…
- Trial name
- NCT01079013
- Testing
- treosulfan
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Sheba Medical Center
Relapsed Follicular Lymphoma
Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma
This is a phase 2, two-arm, non-randomized, open-label, multicenter study evaluating the safety and efficacy of 2 VELCADE-containing regimens.
- Trial name
- NCT00715208
- Testing
- rituximab, cyclophosphamide, doxorubicin
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 55 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Leukemia, Lymphoma
Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies
The purpose of this study is to find out how many irradiated natural killer (NK) cells can be safely given to patients with cancer that has recurred after an autologous stem cell transplant, and to see what effects (good and bad)…
- Conditions
- Leukemia, Lymphoma, Myeloma, Hodgkin's Disease
- Trial name
- NCT00990717
- Testing
- NK-92 cells
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- University Health Network, Toronto
Colitis, Ulcerative
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis
The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT01959282
- Testing
- JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily
- Where
- 97 sites in United States, Australia and 12 more
- Volunteers
- 219 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.